Solid-phase synthesis of (4-threonine)-oxytocin. A more potent and specific oxytocic agent than oxytocin.

No abstract is available for this paper.

• Publication year

  1970

• Venue

  Biochemistry

• Publication date

  1970-09-29

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/BI00822A010PMID 5533681
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synthesis and pharmacological properties of 4-decarboxamido-8-arginine-vasopressin and its 1-deamino analog.

  1970cited by this paper
• Solid-phase syntheis and some pharmacological properties of [8-phenylalanine]-oxytocin.

  1969cited by this paper
• Oxytocin analogs with basic amino acid residues in positions 4 and 5. Synthesis and pharmacological properties of [4-ornithine]- and [5-ornithine]-oxytocin.

  1969cited by this paper
• 4-Proline analogues of neurohypophysial hormones: hypothetical intermediates in peptide evolution.

  1969cited by this paper
• The purification of synthetic oxytocin and analogues by gel filtration on Sephadex G-15.

  1968cited by this paper
• Synthesis by the Merrifield method of a protected nonapeptide amide with the amino acid sequence of oxytocin.

  1968cited by this paper
• The synthesis and pharmacological properties of 4-decarboxamido-8-lysine-vasopressin, 5-decarboxamido-8-lysine-vasopressin, and their 1-deamino analogues.

  1967cited by this paper
• The assay of milk-ejecting activity in the lactating rat.

  1967cited by this paper
• Studies on polynucleotides, XLIX. Stimulation of the binding of aminoacyl-sRNA's to ribosomes by ribotrinucleotides and a survey of codon assignments for 20 amino acids.

  1965cited by this paper
• RNA codewords and protein synthesis, 8. Nucleotide sequences of synonym codons for arginine, valine, cysteine, and alanine.

  1965cited by this paper
• SOLID-PHASE PEPTIDE SYNTHESIS. 3. AN IMPROVED SYNTHESIS OF BRADYKININ.

  1964cited by this paper
• A highly potent analogue of oxytocin, desamino-oxytocin.

  1962cited by this paper
• Effect of magnesium ion on the response of the rat uterus to neurohypophysial hormones and analogues.

  1960cited by this paper
• Differences in the antidiuretic responses of rats to the intravenous administration of lysine and arginine vasopressins.

  1958cited by this paper
• Arginine-vasotocin, a synthetic analogue of the posterior pituitary hormones containing the ring of oxytocin and the side chain of vasopressin.

  1958cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Design of Oxytocin Analogs.

  2019cites this paper
• Cyclic Peptide Design

  2019cites this paper
• Conformations of a model cyclic hexapeptide, CYIQNC: 1H-NMR and molecular dynamics studies

  2015cites this paper
• Conformational studies of neurohypophyseal hormones analogues with glycoconjugates by NMR spectroscopy

  2014cites this paper
• Revisiting oxytocin through the medium of isonitriles.

  2012cites this paper
• Characterization of d‐boroAla as a Novel Broad‐Spectrum Antibacterial Agent Targeting d‐Ala‐d‐Ala Ligase

  2011cites this paper
• Synthesis, pharmacological, conformational, and dynamic studies of the potent hormone antagonists [1-penicillamine, 4-threonine]-oxytocin and [1-penicillamine, 2-phenylalanine, 4-threonine]-oxytocin. Conformational and dynamic considerations in the design of antagonists.

  2009cites this paper
• Synthesis and some pharmacological properties of [Glu(OMe)4]oxytocin and [Mpr1, Glu(OMe)4]oxytocin.

  2009cites this paper
• Benzyloxycarbonylarginine nitrophenyl ester salts: 1-hydroxybenzotriazole catalyzed acylations of amines.

  2009cites this paper
• Solid-phase synthesis of oxytocin, desaminooxytocin and 4-Thr-oxytocin using active esters in presence of 1-hydroxybenzotriazole.

  2009cites this paper
• An acid-labile anchoring linkage for solid-phase synthesis of C-terminal peptide amides under mild conditions.

  2009cites this paper
• Design and synthesis of potent in vivo antagonists of oxytocin.

  2009cites this paper
• Solid-phase peptide synthesis: a silver anniversary report.

  2009cites this paper
• The solid phase synthesis of porcine secretin with full biological activity.

  2009cites this paper
• Impact of the Merrifield solid phase method on the design and synthesis of selective agonists and antagonists of oxytocin and vasopressin: A historical perspective

  2008cites this paper
• Oxytocin analogues with amide groups substituted by tetrazole groups in position 4, 5 or 9.

  2007cites this paper
• Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban

  2005cites this paper
• The deamino derivatives of [4-threonine]-oxytocin and [4-threonine]-mesotocin; Analogs possessing a surprising spectrum of diminished pharmacological activities

  2005cites this paper
• Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.

  2004cites this paper
• Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.

  2002cites this paper
• An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally‐restricted, polar and charged amino acids

  1999cites this paper
• Structural studies with weak oxytocin antagonists

  1996cites this paper
• Solid-phase peptide synthesis.

  1996cites this paper
• Surprising Pharmacological Activity of Analogues Designed by Substitution of Position 3 in Arginine Vasopressin (AVP) and 8‐D‐Arginine Vasopressin with l‐2‐Naphthylalanine

  1996cites this paper
• An exploration of the effects of L‐ and D‐tetrahydroisoquinoline‐3‐carboxylic acid substitutions at positions 2,3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin

  1995cites this paper
• Advances in the design of selective antagonists, potential tocolytics, and radioiodinated ligands for oxytocin receptors.

  1995cites this paper
• Structure--function studies of vasopressin analogues with D-3 pyridyl-alanine in position 2.

  1995cites this paper
• Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists.

  1995cites this paper
• Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin.

  1992cites this paper
• Neuronal‐Glial and Synaptic Plasticity of the Adult Oxytocinergic System

  1992cites this paper
• Cyclic and linear vasopressin V1 and V1/V2 antagonists containing arginine in the 4-position

  1991cites this paper
• The synthesis and biological activity of four novel fluorescent vasopressin analogs.

  1990cites this paper
• Design of potent and selective linear antagonists of vasopressor (V1-receptor) responses to vasopressin.

  1990cites this paper
• IN OXYTOCIN-RECEPTO R BINDING AND BIOLOGICAL ACTIVITY

  1990cites this paper
• The conformation of deamino-oxytocin: X-ray analysis of the 'dry' and 'wet' forms.

  1990cites this paper
• Oxytocin Receptors in the Uterus

  1990cites this paper
• Influence of Ovarian Steroids on the Ultrastructural Plasticity of the Adult Rat Supraoptic Nucleus Induced by Central Administration of Oxytocin

  1990cites this paper
• Conformational and structural considerations in oxytocin-receptor binding and biological activity.

  1990cites this paper
• Invertebrate neuropeptides resembling vasotocin and some analogues: Synthesis and pharmacological properties

  1990cites this paper
• Solid phase peptide synthesis

  1989cites this paper
• Discovery, development, and some uses of vasopressin and oxytocin antagonists.

  1989cites this paper
• Synthesis and some pharmacological properties of three new analogues of arginine-vasopressin modified in positions 1,2,4 and 9.

  1989cites this paper
• Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin.

  1989cites this paper
• Continuous flow peptide synthesis on aminopolyoxyethylene-polystyrene graft copolymer using Fmoc-strategy.

  1988cites this paper
• [4-(0-methyl)-L-threonine] -oxytocin. Synthesis and uterotonic activity.

  1988cites this paper
• Synthesis of 8-D-arginine vasopressin analogues, modified in position 1 as antagonists of the vasopressor response to the parent hormone.

  1988cites this paper
• Synthesis of arginine-vasopressins, modified in positions 1 and 2, as antagonists of the vasopressor response to the parent hormone.

  1988cites this paper
• Synthesis and some pharmacological properties of two new antagonists of oxytocin.

  1987cites this paper
• Chapter 4 – Structure–Activity Relationships of Neurohypophyseal Peptides

  1987cites this paper
• Effect of threonine in position 4 in oxytocin and vasotocin analogs on the time course of uterotonic response.

  1987cites this paper
• CHAPTER 7 – Structure–Activity of the Neurohypophyseal Hormones and Analogs and Implications for Hormone–Receptor Interactions

  1986cites this paper
• Binding studies with rat myometrial and mammary gland membranes on effects of manganese on relative affinities of receptors for oxytocin analogs.

  1986cites this paper
• Synthesis, antidiuretic and pressor activities of [arginine4]arginine-vasopressin and two related analogues.

  1986cites this paper
• Potent and selective antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta,beta-pentamethylenepropionic acid),2-D-isoleucine,4- valine]arginine-vasopressin at position 4.

  1984cites this paper
• Synthesis of the C-terminal undeca- and protected docosapeptide of bovine insulin B-chain.

  1984cites this paper
• Conformational and dynamic considerations in the design of peptide hormone analogs

  1983cites this paper
• Synthesis and some pharmacological properties of oxytocin and vasopressin analogues with sarcosine or N-methyl-L-alanine in position 7.

  1983cites this paper
• Potent antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid),2-D- phenylalanine,4-valine]arginine-vasopressin at position 4.

  1983cites this paper
• Synthesis and some pharmacological properties of [4-threonine,7-sarcosine]oxytocin, a peptide with high oxytocic potency, and of [4-threonine,7-N-methylalanine]oxytocin.

  1983cites this paper
• Design of more potent antagonists of the antidiuretic responses to arginine-vasopressin.

  1982cites this paper
• Design of more potent and selective antagonists of the antidiuretic responses to arginine-vasopressin devoid of antidiuretic agonism.

  1982cites this paper
• Neurohypophysial peptides. Design of tissue-specific agonists and antagonists.

  1981cites this paper
• Chapter 19. Peptides of the Hypothalamus

  1981cites this paper
• Synthetic antagonists of in vivo antidiuretic and vasopressor responses to arginine-vasopressin.

  1981cites this paper
• The design of effective in vivo antagonists of rat uterus and milk ejection responses to oxytocin.

  1980cites this paper
• Synthetic antagonists of in vivo responses by the rat uterus to oxytocin.

  1979cites this paper
• CHAPTER 6 – Biochemical Actions of Neurohypophysial Hormones and Neurophysin

  1979cites this paper
• Purification of human renin.

  1978cites this paper
• [1-Deaminopenicillamine,4-threonine]oxytocin, a potent inhibitor of oxytocin.

  1978cites this paper
• Importance of neurophysin dimer and of tyrosine-49 in the binding of neurohypophyseal peptides.

  1978cites this paper
• Synthesis and some pharmacological properties of [4-homoserine]oxytocin.

  1977cites this paper
• Selectively enriched carbon-13-labeled proline-7 and carbon-13-labeled leucine-8 ocytocins as probes for the analysis of peptide hormone interactions with bovine neurophysin I using carbon-13 nuclear magnetic resonance spectroscopy

  1977cites this paper
• Binding of [(3)H]oxytocin to cells isolated from the mammary gland of the lactating rat

  1977cites this paper
• [1-deaminopenicillamine,4-valine]-8-D-arginine-vasopressin, a highly potent inhibitor of the vasopressor response to arginine-vasopressin.

  1977cites this paper
• Selectively enriched 13C-labeled proline-7 and 13C-labeled leucine-8 ocytocins as probes for the analysis of peptide hormone interactions with bovine neurophysin I using 13C nuclear magnetic resonance spectroscopy.

  1977cites this paper
• Carbon-13 nuclear magnetic resonance studies of the binding of selectively 13C-enriched oxytocins to the neurophypophyseal protein, bovine neurophysin II.

  1977cites this paper
• Synthesis and some pharmacological properties of [4-threonine, 7-glycine]oxytocin, [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine, 7-glycine]oxytocin (hydroxy[Thr4, Gly7]oxytocin), and [7-Glycine]oxytocin, peptides with high oxytocic-antidiuretic selectivity.

  1977cites this paper
• Combined high oxytocic with negligible antidiuretic and pressor activities in multisubstituted oxytocins.

  1977cites this paper
• [1-(L-2-hydroxy-3-mercaptopropanoic acid)] analogues of arginine-vasopressin, [8-D-arginine]vasopressin, and [4-valine,8-D-arginine]vasopressin.

  1977cites this paper
• Preparation of biologically active conjugates of bovine neurophysins and other polypeptides with multi-(poly-D,L-alanyl)--poly-L-lysine and their use to elicit antibodies.

  1977cites this paper
• Synthesis and some pharmacological properties of deamino(4-threonine,8-D-arginine)vasopressin and deamino(8-D-arginine)vasopressin, highly potent and specific antidiuretic peptides, and (8-D-arginine)vasopressin and deamino-arginine-vasopressin.

  1976cites this paper
• Synthesis and some pharmacological properties of [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine]oxytocin (hydroxy [4-thr]oxytocin), a peptide with strikingly high oxytocic potency and of [1-(L-2-hydroxy-3-mercaptopropanoic acid)]oxytocin (hydroxy-oxytocin).

  1976cites this paper
• Synthesis and some pharmacological properties of oxytocin analogues having L-thiazolidine-4-carboxylic acid in position 7.

  1976cites this paper
• 3 – Solid-Phase Peptide Synthesis

  1976cites this paper
• Oxytocin analogues with combined high smooth muscle and negligible antidiuretic activities. Investigation of position 7 in neurohypophyseal hormones.

  1976cites this paper
• Carbon‐13 nuclear magnetic resonance studies on (85% 13C‐enriched Gly9) oxytocin

  1975cites this paper
• Stimulus-response coupling in neurohypophysial peptide target cells.

  1975cites this paper
• Synthesis of [4-histidine]oxytocin

  1975cites this paper
• Carbon-13 nuclear magnetic resonance studies on (85 per cent 13C-enriched Gly 9) oxytocin.

  1975cites this paper
• Oxytocin receptors in rat oviduct.

  1975cites this paper
• Structural changes in the arginine vasopressin molecule that enhance antidiuretic activity and specificity.

  1974cites this paper
• [Chemical synthesis and properties of peptidic hormone analogues (author's transl)].

  1974cites this paper
• Oxytocin receptors in human uterus.

  1974cites this paper
• Characterization of a proposed oxytocin receptor in the uterus of the rat and sow.

  1974cites this paper
• Pharmacology of hydroxy-analogues of oxytocin.

  1974cites this paper
• Proton-Beam Therapy of Pituitary Disease

  1974cites this paper
• Effect of simple amino acid replacements on the biological activity of luteinizing hormone-releasing hormone.

  1973cites this paper
• Oxytocin receptors: oxytocin analogs, but not prostaglandins, complete with 3H-oxytocin for uptake by rat uterus.

  1973cites this paper
• Synthesis and uterotonic activity of [4-methionine]oxytocin

  1973cites this paper
• Characterization of a proposed oxytocin receptor in rat mammary gland.

  1973cites this paper